三官能性抗体
参考資料

↑  Jäger, Michael; Schoberth, Alexandra; Ruf, Peter; Hess, Juergen; Hennig, Michael; Schmalfeldt, Barbara; Wimberger, Pauline; Ströhlein, Michael et al. (2012-01-01). “三官能性抗体Catumaxomab(抗EpCAM×Anti-CD3)による治療を受けた悪性腹水患者の第2/3相試験に関する免疫モニタリング結果（Immunomonitoring Results of a Phase II/III Study of Malignant Ascites Patients Treated with the Trifunctional Antibody Catumaxomab (Anti-EpCAM × Anti-CD3)）” (英語). Cancer Research 72 (1):  24–32. doi:10.1158/0008-5472.CAN-11-2235. ISSN 0008-5472. https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201202234217099283.
↑  Chames, P; Baty, D (2009). “Bispecific antibodies for cancer therapy: the light at the end of the tunnel”. MAbs 1 (6):  1–9. doi:10.4161/mabs.1.6.10015. PMC 2791310. PMID 20073127. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2791310/.
↑  “The trifunctional antibody ertumaxomab destroys tumor cells that express low levels of human epidermal growth factor receptor”. Cancer Research 69 (10):  4270–4276. (2009). doi:10.1158/0008-5472.CAN-08-2861. PMID 19435924.
↑  Reinhard, H (2011). “The effect of trifunctional anti-EpCAM antibody catumaxomab on the development of tumor-specific immune responses in patients with gastric cancer”. Journal of Clinical Oncology 29 (suppl abstr 2601). http://abstract.asco.org/AbstView_102_82824.html.
↑  Ruf, P (2011). “Humoral tumor-associated immune responses induced by catumaxomab in patients with malignant ascites”. Journal of Clinical Oncology 29 (suppl abstr 2575). http://abstract.asco.org/AbstView_102_81293.html.
↑  Lindhofer, H (2009). “Elimination of cancer stem cells (CD133+/EpCAM+) from malignant ascites by the trifunctional antibody catumaxomab: results from a pivotal phase II/III study”. Journal of Clinical Oncology 27 (15s suppl abstr 3014). http://meeting.ascopubs.org/cgi/content/abstract/27/15S/3014?sid=2f0543d8-55df-450e-9038-b796b6e5c902.
↑  Shen, J; Zhu, Z (2008). “Catumaxomab, a rat/murine hybrid trifunctional bispecific monoclonal antibody for the treatment of cancer”. Current Opinion in Molecular Therapeutics 10 (3):  273–284. PMID 18535935.
↑  “Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti-CD3): a phase I study”. Cancer Immunology, Immunotherapy 56 (10):  1637–1644. (2007). doi:10.1007/s00262-007-0310-7. PMID 17410361.
↑  “Phase I trial of the trifunctional antibody anti-HER2/neu x anti-CD3 antibody ertumaxomab in metastatic breast cancer”. Clinical Cancer Research 12 (10):  3085–3091. (2006). doi:10.1158/1078-0432.CCR-05-2436. PMID 16707606.
↑  “Immunotherapy of recurrent B–cell malignancies after allo SCT with Bi20 (FBTA05), a trifunctional anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion”. Bone Marrow Transplantation 43 (5):  383–397. (2008). doi:10.1038/bmt.2008.323. PMID 18850012.
↑  Boehrer, Simone; Schroeder, Petra; Mueller, Tina; Atz, Judith; Chow, Kai Uwe (2011). “Cytotoxic effects of the trifunctional bispecific antibody FBTA05 in ex-vivo cells of chronic lymphocytic leukaemia depend on immune-mediated mechanism”. Anti-Cancer Drugs 22 (6):  519–530. doi:10.1097/CAD.0b013e328344887f. ISSN 0959-4973. PMID 21637160.
↑  “Two new trifunctional antibodies for the therapy of human malignant melanoma”. International Journal of Cancer 108 (5):  725–32. (2004). doi:10.1002/ijc.11630. PMID 14696099.
↑  Staerz, UD; Kanagawa, O; Bevan, MJ (1985). “Hybrid antibodies can target sites for attack by T cells”. Nature 314 (6012):  628–31. Bibcode: 1985Natur.314..628S. doi:10.1038/314628a0. PMID 2859527.
↑  Mueller, D; Kontermann, RE (2010). “Bispecific antibodies for cancer immunotherapy”. BioDrugs 24 (2):  89–98. doi:10.2165/11530960-000000000-00000. PMID 20199124.
↑  Ott (2010). “The trifunctional antibody catumaxomab: correlation between immunological response and clinical outcome – new analysis of pivotal phase II/III study”. Journal of Clinical Oncology 28 (15s suppl abstr 2551). http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID=49128.
↑  “First patient treated with a re-challenge of catumaxomab in recurrent malignant ascites: a case report”. Medical Oncology 29 (2):  1391–6. (2012). doi:10.1007/s12032-011-9961-5. PMID 21544631.
↑  “The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial”. International Journal of Cancer 127 (9):  2209–21. (2010). doi:10.1002/ijc.25423. PMC 2958458. PMID 20473913. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2958458/.
↑  Kufer, P; Lutterbüse, R; Baeuerle, PA (2004). “A revival of bispecific antibodies”. Trends in Biotechnology 22 (5):  238–44. doi:10.1016/j.tibtech.2004.03.006. PMID 15109810.
↑  Lindhofer, H; Mocikat, R; Steipe, B; Thierfelder, S (1995). “Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies”. Journal of Immunology 155 (1):  219–25. PMID 7602098.